Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
VA Office of Research and Development
320 participants
Jun 21, 2023
INTERVENTIONAL
Conditions
Summary
Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differing from that of civilians, a well-structured clinical trial of cannabinoids for Veterans with CNP is vital.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive a target dose of 10mg per day of THC (Syndros).
Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
Placebo
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05351801